On Tuesday, the US Food and Drug Administration (FDA) published new draft guidance to help trading partners in the pharmaceutical supply chain request waivers or exemptions from requirements in the Drug Supply Chain and Security Act (DSCSA).
The DSCSA, which was signed into law in 2013, aims to build a system by 2023 to identify and trace pharmaceuticals as they are distributed through the US supply chain, including the requirement of placing unique identifiers on medicine packaging that can...
Read More